

STROBE Statement Checklist for Cohort Studies (Final Updated Version)

Manuscript: Thyroid Autoimmunity at Onset of Type 1 Diabetes as a Predictor of Thyroid Dysfunction: a thirty-years retrospective longitudinal study

This checklist reflects the final accepted version of the manuscript, incorporating all revisions and corresponding line references.

Item No.	STROBE Recommendation	Included (Yes/No/NA)	Line(s) in Manuscript / Comments
1	Indicate the study's design with a commonly used term in the title or abstract.	Yes	Title lines 1–20 Abstract, 41-42
2	Explain the scientific background and rationale for the investigation.	Yes	Introduction, lines 59-80
3	State specific objectives, including any prespecified hypotheses.	Yes	Introduction, lines 76-80
4	Present key elements of study design early in the paper.	Yes	Methods, lines 125-129
5	Describe the setting, locations, and relevant dates, including periods of recruitment and follow-up.	Yes	Methods, lines 83-129
6	Give eligibility criteria and sources/methods of selection of participants.	Yes	Methods, lines 120–140
7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.	Yes	Methods, lines 83-94
8	For each variable, give sources of data and details of assessment methods.	Yes	Methods, lines 06-129
9	Describe any efforts to address potential sources of bias.	Yes	Methods, lines 92-94, 120-122, 147-149. Discussion, lines 279-299

10	Explain how the study size was arrived at.	Yes	Methods, lines 83-94 (n=160 after exclusions)
11	Explain how quantitative variables were handled in the analyses.	Yes	Methods, lines 134-147
12	Describe all statistical methods, including those used to control for confounding.	Yes	Methods, lines 131-149
13	Describe methods used to examine subgroups and interactions.	Yes	Methods, lines 128-129 (stratified by age at onset)
14	Explain how missing data were addressed.	Yes	Methods, lines 140-141 (case-wise exclusion for missing ICA)
15	If applicable, explain how loss to follow-up was addressed.	Yes	Methods, lines 118-122; Results, lines 175-179
16	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% CI).	Yes	Results, lines 170-201; Table 2
17	Report numbers of individuals at each stage of the study.	Yes	Results, lines 151-164, 186-189
18	Give characteristics of study participants and information on exposures/confounders.	Yes	Results, Table 1,
19	Report numbers of outcome events or summary measures over time.	Yes	Results, lines 152-167
20	Give main results with measures of precision (e.g., 95% CI).	Yes	Results, Table 2, lines 170-201
21	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	Yes	Discussion, lines 279-299 (Strengths and limitations)
22	Give a cautious overall interpretation of results considering objectives,	Yes	Discussion, lines 304-312

	limitations, and other evidence.		
23	Discuss the generalisability (external validity) of the study results.	Yes	Discussion, lines 304-312
24	Give the source of funding and the role of the funders.	Yes	Funding section, Line 317